

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 December 2002 (05.12.2002)

PCT

(10) International Publication Number
WO 02/097038 A3

- (51) International Patent Classification⁷: **A61K 38/16**, 38/19, C07K 14/00, 14/435, 14/475, 14/52, 19/00
- (21) International Application Number: PCT/US02/16525
- (22) International Filing Date: 24 May 2002 (24.05.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/293,212 25 May 2001 (25.05.2001) US
- (71) Applicant (for all designated States except US): **HUMAN GENOME SCIENCES, INC.** [US/US]; 9410 Key West Avenue, Rockville, MD 20850 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BELL, Adam** [US/US]; 13312 Burnt Woods Place, Germantown, MD 20874 (US). **RUBEN, Steven, M.** [US/US]; 18528 Heritage Hills Drive, Olney, MD 20832 (US).
- (74) Agents: **WALES, Michele, M.** et al.; Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD 20850 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
9 October 2003
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **CHEMOKINE BETA-1 FUSION PROTEINS**

(57) Abstract: The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck\$G(b)-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-gamma, and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.

WO 02/097038 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/16525

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/16, 38/19; C07K 14/00, 14/435, 14/475, 14/52, 19/00

US CL : 530/350; 514/2, 12; 424/85.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/350; 514/2, 12; 424/85.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
GenBank, EMBL, PIR, SwissProt sequence databases**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|---------------|---|------------------------------|
| X --- Y | WO 98/07862 A2 (HUMAN GEOME SCIENCES, INC.) 26 February 1998, see entire document. | 1 ----- 3,4,6-10,12-14 |
| X --- Y | US 6,180,773 B1 (FORSSMANN et al) 30 January 2001, see entire document. | 1 ----- 3,4,6-10,12-14 |
| A --- | SCHULZ-KNAPPE, P. et al. HCC-1, a Novel Chemokine from Human Placenta. Journal of Experimental Medicine. January 1996, Vol. 183, pages 295-299, see entire document. | 1-4, 6-10, 12-14 |
| A --- | PARDIGOL, A. et al. HCC-2, a human chemokine: Gene structure, expression pattern, and biological activity. Proc. Natl. Acad. Sci. USA. May 1998, Vol. 95, pages 6308-6313, see entire document. | 1-4, 6-10, 12-14 |
| A --- | NOMIYAMA, H. et al. Organization of the Chemokine Gene Cluster on Human Chromosome 17q11.2 Containing the Genes for CC Chemokine MPIF-1, HCC-2, HCC-1, LEC, and RANTES. Journal of Interferon and Cytokine Research. 1999, Vol. 19, pages 227-234, see entire document. | 1-4, 6-10, 12-14 |

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

| | |
|---|--|
| * Special categories of cited documents: | |
| "A" document defining the general state of the art which is not considered to be of particular relevance | "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention |
| "E" earlier application or patent published on or after the international filing date | "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone |
| "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| "O" document referring to an oral disclosure, use, exhibition or other means | "&" document member of the same patent family |
| "P" document published prior to the international filing date but later than the priority date claimed | |

Date of the actual completion of the international search

15 May 2003 (15.05.2003)

Date of mailing of the international search report

21 JUL 2003

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703)305-3230

Authorized officer

Yvonne L. Eyler, Ph.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/16525

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claim Nos.: 5
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
the claims recite SEQ ID NO: X. Since no numerical value was provided for the sequence identifier, the sequence search could not be performed.
3. ☒ Claim Nos.: 11, 15-17
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

least one molecule of a Ckb1 protein (or fragment or variant thereof). Ckb1 protein is also referred to herein as "therapeutic protein". As used herein, "albumin fusion protein" refers to a protein formed by the fusion of at least one molecule of albumin (or a fragment or variant thereof) to at least one molecule of a Ckb1 protein (or fragment or variant thereof). A fusion protein (e.g. albumin fusion protein) of the invention comprises at least a fragment or variant of a Ckb1 protein and at least a fragment or variant of a heterologous protein (e.g. human serum albumin), which are associated with one another, preferably by genetic fusion (i.e., the fusion protein (e.g. albumin fusion protein) is generated by translation of a nucleic acid in which a polynucleotide encoding all or a portion of a Ckb1 protein is joined in-frame with a polynucleotide encoding all or a portion of the heterologous protein (e.g. albumin)) or chemical conjugation to one another. The Ckb1 protein and heterologous (e.g. albumin) protein, once part of the fusion protein, may be referred to as a "portion", "region" or "moiety" of the fusion protein (e.g. albumin fusion protein) (e.g., "Ckb1 protein portion"; "heterologous protein portion"; "albumin protein portion").

[0055] A fusion protein of the invention comprises, or alternatively consists of, one or more heterologous polypeptides, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or more heterologous polypeptides. The heterologous protein may be of any length, from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, etc., amino acids to 100, 500, 1000, etc., amino acids in length. The heterologous proteins may be fused or conjugated anywhere such as at the N-terminus or the C-terminus of Ckb1, and may be of any length. In some preferred embodiments, the heterologous polypeptide is albumin, preferably fused at the C-terminus. In some preferred embodiments, the heterologous polypeptide is a translocation signal, such as a secretion signal, preferably fused at the N-terminus. The translocation signal may be mammalian, vertebrate, eukaryotic, prokaryotic, yeast, bacterial, human, mouse, chicken, E. coli, etc. Preferably, the translocation signal is yeast. In some preferred embodiments, the Ckb1 polypeptide comprises, or alternatively consists of, an N-terminal yeast secretion signal and a C-terminal albumin.

[0056] Human serum albumin (HSA, or HSA), a protein of 585 amino acids in its mature form (as shown in Figure 14 or in SEQ ID NO:5), is responsible for a significant proportion of the osmotic pressure of serum and also functions as a carrier of endogenous and exogenous ligands. At present, HSA for clinical use is produced by extraction from

human blood. The production of recombinant HSA (r HSA) in microorganisms has been disclosed in EP 330 451 and EP 361 991.

[0057]The role of albumin as a carrier molecule and its inert nature are desirable properties for use as a carrier and transporter of polypeptides *in vivo*. Fusion of albumin to the Ckb1 protein may be achieved by genetic manipulation, such that the DNA coding for HSA, or a fragment thereof, is joined to the DNA coding for the Ckb1 protein. A suitable host is then transformed or transfected with the fused nucleotide sequences, so arranged on a suitable plasmid as to express a fusion polypeptide. The expression may be effected *in vitro*, for example, prokaryotic or eukaryotic cells, or *in vivo* e.g. from a transgenic organism.

[0058]In one embodiment, the invention provides a fusion protein (e.g. albumin fusion protein) comprising, or alternatively consisting of, a Ckb1 protein (e.g., Ck β -1) and a serum albumin protein. In other embodiments, the invention provides a fusion protein (e.g. albumin fusion protein) comprising, or alternatively consisting of, a biologically active and/or therapeutically active fragment of a Ckb1 protein and a serum albumin protein. In other embodiments, the invention provides a fusion protein (e.g. albumin fusion protein) comprising, or alternatively consisting of, a biologically active and/or therapeutically active variant of a Ckb1 protein and a serum albumin protein. In preferred embodiments, the serum albumin protein component of the fusion protein (e.g. albumin fusion protein) is the mature portion of serum albumin.

[0059]In further embodiments, the invention provides a fusion protein (e.g. albumin fusion protein) comprising, or alternatively consisting of, a Ckb1 protein, and a biologically active and/or therapeutically active fragment of serum albumin. In further embodiments, the invention provides a fusion protein (e.g. albumin fusion protein) comprising, or alternatively consisting of, a Ckb1 protein and a biologically active and/or therapeutically active variant of serum albumin. In preferred embodiments, the Ckb1 protein portion of the fusion protein (e.g. albumin fusion protein) is the mature portion of the Ckb1 protein. In a further preferred embodiment, the Ckb1 protein portion of the fusion protein (e.g. albumin fusion protein) is a soluble domain of the Ckb1 protein. In an alternative embodiment, the Ckb1 protein portion of the fusion protein (e.g. albumin fusion protein) is the active form of the Therapeutic protein.

[0060]In a further preferred embodiment, an albumin fusion protein of the invention is processed by a host cell and secreted into the surrounding culture medium, and then

Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
 565 570 575
 gct gca agt caa gct gcc tta ggc ttataacatc tacattttaa agcatctcag 1782
 Ala Ala Ser Gln Ala Ala Leu Gly
 580

<210> 5
 <211> 584
 <212> PRT
 <213> Homo Sapiens

<400> 5

Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
 1 5 10 15

Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
 20 25 30

Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
 35 40 45

Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
 50 55 60

Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu
 65 70 75 80

Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro
 85 90 95

Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu
 100 105 110

Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His
 115 120 125

Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg
 130 135 140

Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg
 145 150 155 160

Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala
 165 170 175

Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser
 180 185 190

Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu
 195 200 205

Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro
 210 215 220

Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys
225 230 235 240

Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp
245 250 255

Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser
260 265 270

Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His
275 280 285

Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser
290 295 300

Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala
305 310 315 320

Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg
325 330 335

Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr
340 345 350

Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala Asp Pro His Glu
355 360 365

Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro
370 375 380

Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu
385 390 395 400

Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro
405 410 415

Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys
420 425 430

Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
435 440 445

Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His
450 455 460

Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser
465 470 475 480

Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr
485 490 495

Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp
500 505 510

Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala
515 520 525

Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu
530 535 540

Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys
545 550 555 560

Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val
565 570 575

Ala Ala Ser Gln Ala Ala Leu Gly Leu
580 585

<210> 6

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> Linker peptide that may be used to join VH
and VL domains in an scFv.

<400> 6

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10 15

<210> 7<211> 609<212> PRT<213> Homo Sapiens<400> 7

Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
1 5 10 15

Tyr Ser Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala
20 25 30

His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu
35 40 45

Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val
50 55 60

Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp
65 70 75 80

Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp
85 90 95

Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala
100 105 110